AUR-106 - Aurigene
JIVAN: A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies (clinicaltrials.gov) - Apr 18, 2026 - P1 | N=21 | Terminated | Sponsor: Aurigene Discovery Technologies Limited | N=30 ➔ 21 | Trial completion date: Jun 2025 ➔ Feb 2026 | Recruiting ➔ Terminated | Trial primary completion date: May 2025 ➔ Feb 2026; Patient recruitment problems 
Enrollment change • First-in-human • Trial completion date • Trial primary completion date • Trial termination • Colon Cancer • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Genito-urinary Cancer • Kidney Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer
http://clinicaltrials.gov/ct2/show/NCT05861947
 
Apr 18, 2026
 
Prev Next